Diatech files INDs for two peptides
Peptide-based imaging agent developer Diatech has filed two investigationalnew drug (IND) applications with the Food and Drug Administrationfor technetium-99m-labeled radiopharmaceuticals. Diatech, of Londonderry,NH, reported the news this month. The
Peptide-based imaging agent developer Diatech has filed two investigationalnew drug (IND) applications with the Food and Drug Administrationfor technetium-99m-labeled radiopharmaceuticals. Diatech, of Londonderry,NH, reported the news this month.
The first agent, Tc-99m P748, is for the rapid detection ofpulmonary embolism. The peptide binds to a glycoprotein receptorlocated at activated platelets involved in blood clots. The secondagent, Tc-99m P829, is a somatostatin peptide for localizing canceroustumors. Diatech claims that a study presented at last year's RadiologicalSociety of North America meeting indicated that an agent closelyrelated to P829 may have better target to non-target ratios comparedto OctreoScan, a peptide-based imaging agent released by MallinckrodtMedical last year (SCAN 6/15/94).
The IND filings bring to five the number of Diatech productsin clinical trials, according to Diatech president Richard Dean.Diatech is also developing peptide-based radiopharmaceuticalsfor the detection of deep-vein thrombosis and atherosclerosisand for the treatment of bone metastases.
Study: Monitoring of Prostate MRI Exams Could Lead to 75 Percent Reduction of Gadolinium Contrast
March 17th 2025While DCE MRI was deemed helpful in over 67 percent of cases in which it was used, researchers found that monitored prostate MRI exams, which facilitated a 75 percent reduction of DCE MRI sequences, had comparable sensitivity for prostate cancer as non-monitored exams.
